Description
Accession
Q8N423
Source
DNA sequence encoding Human LILRB2/CD85d/ILT4 including a C-mFc tag was expressed in HEK293 Cells.
Molecular weight
Recombinant Human LILRB2/CD85d/ILT4 is a protein consisting of amino acid residues [Gln22-His458] ,The protein has a predicted MW of 73.6 kDa. Due to glycosylation, the protein migrates to 80-110 kDa based on Tris-Bis PAGE result..
Purity
>95%, as determined by SDS-PAGE and HPLC
Biological Activity
see methods section
Endotoxin
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation
Recombinant Human LILRB2/CD85d/ILT4 was lyophilized from 0.2 µm filtered PBS solution pH7.4
Reconstitution
Centrifuge vial to ensure maximal product extraction, recommended:20sec, 5K RPM
Storage
The lyophilized protein is stable for at least 2 years from date of receipt at -20° C.
Usage
This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Interactor
Q86XS5
Interactor
Biological Process
Molecular function
Methods
Human LILRB2/CD85d/ILT4 Protein Tris-Bis PAGE
- Human LILRB2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Human LILRB2/CD85d/ILT4 Protein SEC-HPLC
- The purity of Human LILRB2 is greater than 95% as determined by SEC-HPLC.
Human LILRB2/CD85d/ILT4 Protein ELISA Data
- Immobilized Human LILRB2, mFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB2 Antibody, hFc Tag with the EC50 of 11.4ng/ml determined by ELISA.
Human LILRB2/CD85d/ILT4 Protein Blocking Data
- Serial dilutions of Anti-LILRB2 Antibody were added into Human HLA-G Complex Tetramer, His Tag : Human LILRB2, mFc Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.11μg/ml.
